New treatment options for patients with advanced neuroendocrine tumors

  • J.A. C
  • M.H. K
  • 3

    Readers

    Mendeley users who have this article in their library.
  • N/A

    Citations

    Citations of this article.

Abstract

Opinion statement: Well- to moderately differentiated neuroendocrine tumors (NET) are a heterogeneous group of malignancies for which a range of therapeutic options have been employed. For patients with localized NET, surgical resection remains the mainstay of treatment. Surgical resection of hepatic metastases or hepatic artery embolization may also be beneficial in patients with hepatic-predominant metastatic disease. Symptoms of hormonal excess, such as carcinoid syndrome and syndromes associated with functional pancreatic NET, can be effectively treated with somatostatin analogs. Systemic treatment options for patients with advanced NET have been limited. Treatment with the somatostatin analog octreotide has been shown to improve progression-free survival in patients with advanced midgut carcinoid tumors, and the potential antiproliferative effect of somatostatin analogs in patients with other NET subtypes is currently under investigation. Patients with advanced pancreatic NET may also respond to treatment with streptozocin or temozolomide-based therapy. In patients with advanced pancreatic NET, randomized, placebo-controlled studies have recently demonstrated that treatment with the tyrosine kinase inhibitor sunitinib or with the mTOR inhibitor everolimus is associated with improved progression-free survival. Based on these studies, sunitinib or everolimus should now be considered as therapeutic options in patients with advanced pancreatic NET. Initial phase II studies have also suggested activity associated with VEGF pathway and mTOR inhibitors in patients with advanced carcinoid tumors. Future studies will likely further define the role of these agents in the advanced carcinoid patient population. (copyright) 2011 Springer Science+Business Media, LLC.

Author-supplied keywords

  • alpha interferon
  • angiopeptin
  • antineoplastic activity
  • antineoplastic agent
  • article
  • artificial embolism
  • bevacizumab
  • bone marrow suppression
  • cancer combination chemotherapy
  • cancer surgery
  • capecitabine
  • carcinoid
  • carcinoid syndrome
  • chemoembolization
  • chlorozotocin
  • clinical trial (topic)
  • cytoreductive surgery
  • doxorubicin
  • drug dose escalation
  • drug dose titration
  • drug efficacy
  • drug protein binding
  • drug safety
  • drug tolerability
  • edotreotide y 90
  • everolimus
  • fluorouracil
  • human
  • liver metastasis
  • low drug dose
  • lutetium 177
  • mammalian target of rapamycin inhibitor
  • nephrotoxicity
  • neuroendocrine tumor
  • octreotide
  • outcome assessment
  • pancreas cancer
  • pancreas neuroendocrine tumor
  • pancreas tumor
  • pasireotide
  • pazopanib
  • peginterferon alpha2b
  • placebo
  • prognosis
  • progression free survival
  • rad 001
  • signal transduction
  • som 230
  • somatostatin derivative
  • sorafenib
  • stomach carcinoid
  • streptozocin
  • sunitinib
  • temozolomide
  • temsirolimus
  • thalidomide
  • tumor differentiation
  • unclassified drug
  • unspecified side effect
  • yttrium 90

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • Chan J.A.

  • Kulke M.H.

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free